Orange Book product · Brand (NDA)
AMITIZA
LUBIPROSTONE
At a glance
Jan 31, 2006
Approved
Brand (NDA)
Application
AB
TE code
3
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 31, 2006
20 yr 8 mo ago
Today
Patent 8338639 expires
Listed drug product patent expiration.
Jan 23, 2027
in 7 mo
Patent 8779187 expires
Listed drug product patent expiration.
Jan 23, 2027
in 7 mo
Patent 8026393 expires
Listed drug product patent expiration.
Oct 25, 2027
in 1 yr 4 mo
Pharmaceutical detail
Active ingredient
LUBIPROSTONE
Strength
24MCG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
NDA 021908
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025LUBIPROSTONEGeneric (ANDA)
ANDA 218640 · ASCENT PHARMS INC
- 2023LUBIPROSTONEGeneric (ANDA)
ANDA 214131 · ZYDUS PHARMS
- 2022LUBIPROSTONEGeneric (ANDA)
ANDA 201442 · PH HEALTH
- 2022LUBIPROSTONEGeneric (ANDA)
ANDA 206994 · DR REDDYS
- 2022LUBIPROSTONEGeneric (ANDA)
ANDA 209920 · TEVA PHARMS USA INC
- 2021LUBIPROSTONEGeneric (ANDA)
ANDA 209450 · AMNEAL
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8338639 | Jan 23, 2027 | in 7 mo | Product |
| 8779187 | Jan 23, 2027 | in 7 mo | Product |
| 8026393 | Oct 25, 2027 | in 1 yr 4 mo | Product |

